TechnoPhage
TechnoPhage is a Lisbon-based clinical-stage biopharmaceutical company developing bacteriophage cocktails, antibody fragments, and repurposed small molecules across infection, neuroscience, and ophthalmology indications, with lead asset TP-102 advancing toward Phase 3.
- Company typePrivate
- Founded2005
- HeadquartersLisbon, Portugal
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What TechnoPhage does
TechnoPhage, S.A. is a Lisbon-headquartered, privately held clinical-stage biopharmaceutical company founded in 2005 that develops biological and chemical therapeutics across three proprietary platforms spanning infection, neurosciences, and ophthalmology. The company's core technology combines bacteriophage-based biologics, antibody fragment discovery, and a proprietary zebrafish drug screening platform used to repurpose FDA-approved small molecules. Its lead asset, TP-102, is a five-phage cocktail targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii in infected diabetic foot ulcers; TP-102 received FDA Fast Track Designation in May 2021, completed Phase I/IIa in December 2022, completed an 80-patient Phase 2b (REVERSE 2) in December 2025, and is positioned for Phase 3 development. The pipeline is broadened by TP-122 (a phage therapy in Phase 1/2a approved in Europe in June 2026), TZ-161 (a repurposed small molecule in Phase 1b/2a for acute spinal cord injury under the eSpine study since July 2025), TA-201 (a COVID-19 antibody fragment funded by Portugal 2020), and TZ-113 (a Parkinson's dyskinesia program).
TechnoPhage owns and operates an INFARMED-authorized GMP manufacturing facility in Venda Nova, Amadora, one of few in Portugal certified for production of bacteriophages and antibody fragments, and holds 166 live patents across 25 jurisdictions. The company is part of the Technophage Group alongside VectorB2B (a 2019 collaborative drug discovery and contract research platform) and LX Bio – Pharmaceuticals (a 2021 spin-off focused on late-phase clinical trials, production, and commercialization, with a new €40–60M facility planned).
The company is pre-revenue and finances operations primarily through non-dilutive Portuguese public funding, including a €500K Portugal 2020/FEDER grant in 2020 and a €5,442,437.19 PRR grant in 2022 as part of the €35M Bio-Hub consortium. Its go-to-market combines enterprise sales to clinical trial sites and hospital systems across the US, India, Israel, Portugal, and the Netherlands with strategic co-development partnerships (notably the January 2025 PHAXIAM collaboration for Individualized Phage Therapies) and contract GMP manufacturing services for third parties. Future revenue is expected to derive from product commercialization of TP-102, TP-122, and TZ-161 upon regulatory approval, supplemented by licensing royalties and CRO/contract manufacturing income.
TechnoPhage firmographics
Firmographics- Name
- TechnoPhage
- Legal name
- TechnoPhage, SA
- Website
- https://technophage.pt
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TechnoPhage is a Lisbon-based clinical-stage biopharmaceutical company developing bacteriophage cocktails, antibody fragments, and repurposed small molecules across infection, neuroscience, and ophthalmology indications, with lead asset TP-102 advancing toward Phase 3.
- Ownership category
- akta.pro rank
Where TechnoPhage is headquartered
LocationHeadquarters
- HQ city
- Lisbon
- HQ country
- Portugal
- HQ region
- Europe
Offices2 records
Markets served
TechnoPhage business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Biopharmaceutical Development and Commercialization: TechnoPhage develops proprietary biopharmaceutical products (TP-102, TP-122, TZ-161) through clinical trials with the aim of commercializing them upon regulatory approval. Revenue will be generated through product sales targeting diabetic foot infections, spinal cord injuries, and antimicrobial-resistant infections.
- Contract Manufacturing Services (GMP): TechnoPhage offers GMP manufacturing services to other national and international companies. The company has INFARMED-certified manufacturing facilities for biologics production including bacteriophages and antibody fragments.
- Collaborative R&D and Licensing: TechnoPhage receives funding through PRR (Recovery and Resilience Plan) grants and collaborates with partners for drug development, receiving compensation for research services and technology licensing.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
TechnoPhage product offering
Product offeringCore offering
TechnoPhage is a clinical-stage biopharmaceutical company developing bacteriophage-based therapeutics, antibody fragments, and repurposed small molecules for infections, neurological disorders, and ophthalmology. Its lead asset TP-102 is a five-phage cocktail for diabetic foot ulcers with FDA Fast Track designation, supported by an in-house INFARMED-certified GMP plant that also offers contract manufacturing for biologics.
Product overview
TechnoPhage is a clinical-stage biopharmaceutical company that develops biological and chemical products using three proprietary technology platforms for infection, neurosciences, and ophthalmology therapeutic areas. The company's core product pipeline includes TP-102 (bacteriophage cocktail for infected diabetic foot ulcers), TP-122 (bacteriophage product in Phase 1/2a), and TZ-161 (repurposed small molecule for spinal cord injury in Phase 1b/2a). Additional pipeline products include TA-201 (COVID-19 therapeutic antibody) and TZ-113 (Parkinson's disease therapy). TechnoPhage operates its own GMP-certified manufacturing plant specializing in biologics production including bacteriophages and antibody fragments, with subsidiary LX Bio handling industrialization and VectorB2B providing integrated drug discovery and development services. The company has a portfolio of 166 live patents across 25 jurisdictions.
Differentiator
Problem solved
Functional benefit
Products and services
- TP-102 Bacteriophage Cocktail Lead clinical asset consisting of five bacteriophages for topical treatment of infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii; FDA Fast Track designation, Phase I/IIa and Phase 2b completed.
- TP-122 Bacteriophage Product Bacteriophage therapeutic product for treatment of severe resistant infections; regulatory approval received to initiate Phase 1/2a clinical study TP-122_101A in Europe (Portugal and Netherlands).
- TZ-161 Spinal Cord Injury Treatment Repurposed approved small molecule identified through TechnoPhage's zebrafish screening platform for treatment of acute spinal cord injury; currently in Phase 1b/2a (eSpine) study in Spain and Portugal.
- TA-201 COVID-19 Therapeutic Antibody Neutralizing antibody fragment identified from blood samples of COVID-19 patients, designed for administration via nebulization for COVID-19 treatment.
- TZ-113 Parkinson's Disease Program Repurposing project targeting levodopa-induced dyskinesia during OFF periods in Parkinson's patients; US patent application No. 15/568,655 allowed.
- GMP Manufacturing Services GMP-certified contract manufacturing of biologics including bacteriophages and antibody fragments at the Venda Nova, Amadora plant, authorized by INFARMED for manufacture and analysis of medicines for clinical trial use.
Quantifiable outcome
- TP-102 Phase I/IIa demonstrated safety and tolerability with no adverse events reported; reduced bacterial load in infected ulcers and showed wound healing potential
- +2 more outcomes
Companies that use TechnoPhage
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
TechnoPhage technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
TechnoPhage partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- PHAXIAM TherapeuticscoreStrategic collaboration on Individualized Phages Therapies (IPT) combining GMP phage portfolios. Partnership aims to achieve 25 GMP phages by end of 2025 and 35-40 by end of 2026, targeting at least seven critical pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae, and Acinetobacter baumannii.
- JSS Medical ResearchcoreCRO responsible for managing TP-102 REVERSE 2 clinical trial in India. Collaboration with Principal Investigators from various clinical trial sites.
- University of MacauminorCollaboration since 2014 on C1 bioactive compound development. Professor Simon Lee presented efficacy data while Technophage focused on manufacturing process, analytical data, toxicology study and regulatory perspective for novel food ingredient derived from Chinese plant.
- LX Bio – PharmaceuticalscoreCo-promoter of Bio-Hub National R&D Platform for Production, Commercialization and Distribution of Innovative Biopharmaceuticals. LX Bio leads the consortium aiming to expand development of biological medicines, conduct late-phase clinical trials, and implement global marketing and distribution from Portugal. €19M incentive out of €35M total investment.
- VectorB2B – Drug DevelopingcoreCo-promoter of Bio-Hub consortium, providing drug development platform that gathers academic and industrial capacities in health biotechnology. Transforms capacities into viable economical assets through integrated services in drug discovery, project design, contract research and manufacturing.
- Faculty of Pharmacy, University of Lisbon (FFUL)coreCo-promoter of Bio-Hub consortium providing academic research capabilities and expertise in pharmaceutical sciences for the development of innovative biological medicines.
- ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde)coreCollaboration on Alzheimer's Disease diagnostic solution in PET imaging. ICNAS contributes expertise in development of radiochemicals including First in Human studies, combined with Technophage's antibody discovery and GMP production capabilities.
- Medinfar GroupcoreCollaboration on COVID-19 therapeutic antibody (TA-201) development. Medinfar Group and Recipharm Venture Fund partnership for developing and validating new commercial biomarker for imaging beta-amyloid for early diagnosis of Alzheimer's Disease.
- Johnson & Johnson Innovation, JLABSminorTechnophage is a resident company of JLABS, a premier life science incubator program. Global network of open innovation ecosystems enabling and empowering innovators to create and accelerate delivery of life-enhancing health and wellness solutions.
- Instituto de Medicina Molecular João Lobo Antunes (iMM)minorCollaboration with team led by Leonor Saúde on zebrafish screening platform development for drug discovery and selection for spinal cord injuries. Published in Scientific Reports journal.
- BEAM AllianceminorTechnoPhage is a Founding Member of BEAM Alliance, the alliance of Biotech's of Europe innovating in Anti-Microbial Resistance.
- Faculty of Veterinary Medicine, University of LisbonminorSigned collaboration agreement for joint research and development activities in veterinary biotechnology applications.
- BialminorResearch collaboration on antibodies for Alzheimer's disease with Instituto de Medicina Molecular and Bial. Research featured in news article.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
TechnoPhage competitors and assessment
Company assessmentDirect peers
- Intralytix: U.S.-based biotechnology company developing bacteriophage-based products for bacterial control in human health, food safety, and animal health. Comparable as a phage-product developer with manufacturing capabilities and a multi-application platform analogous to TechnoPhage's three therapeutic pillars.
- PHAXIAM Therapeutics: French clinical-stage biopharmaceutical company (formerly Pherecydes Pharma) focused on phage therapy for resistant bacterial infections. Directly comparable as a phage therapy specialist and an active TechnoPhage partner via the January 2025 strategic collaboration on Individualized Phage Therapies.
- Armata Pharmaceuticals: U.S. clinical-stage biotechnology company developing purified bacteriophage therapies for antibiotic-resistant infections (including Staphylococcus aureus bacteremia and Pseudomonas aeruginosa lung infections). Directly comparable as a phage-therapy pure-play competing in overlapping indications.
- Adaptive Phage Therapeutics: U.S. clinical-stage company developing personalized phage therapy with a focus on individualized matching of phages to patient-specific pathogens. Directly comparable through its individualized phage therapy model targeting resistant infections, similar in mechanism to the PHAXIAM-TechnoPhage partnership strategy.
- Locus Biosciences: U.S. clinical-stage biotechnology company developing engineered phage therapies (crispr-enhanced precision phage products) targeting antibiotic-resistant infections. Directly comparable as a phage-therapy developer overlapping with TechnoPhage's infection indications.
Others
- Hovione: Portuguese-founded contract development and manufacturing organization (CDMO) specialized in active pharmaceutical ingredients and inhaled drug delivery. Comparable as a Lisbon-headquartered biopharmaceutical manufacturing and drug-delivery company, providing ecosystem context for the Portuguese biopharma sector in which TechnoPhage operates.
Emerging players
- Eligo Bioscience: French biotech developing engineered phage-derived particles (eligobiotics) for microbiome precision editing, including acne and antimicrobial-resistant infections. Comparable as a next-generation phage-platform company addressing similar resistant-infection use cases with a differentiated delivery technology.
- ContraFect Corporation: U.S. clinical-stage biotechnology company developing lysin-based and direct lytic agents against drug-resistant bacterial pathogens. Comparable as an anti-infective biological platform targeting resistant infections through a non-traditional antibiotic mechanism.
Regional players
- Bial — Portela & Cª, S.A. Privately held Portuguese pharmaceutical company with a CNS-focused portfolio and active Alzheimer's research partnerships. Comparable as a Portuguese biopharma operating in overlapping geographies and central nervous system indications (TechnoPhage's TZ-113/TZ-161).
- Medinfar Group: Portuguese pharmaceutical group partnering with TechnoPhage on COVID-19 antibody (TA-201) and Alzheimer's biomarker development. Comparable as a domestic pharma partner operating in the same Iberian innovation ecosystem and a current TechnoPhage collaborator.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TechnoPhage social profiles
Digital presenceTechnoPhage compliance and trust
Trust signalCompliance15 records
TechnoPhage financial estimates
Financial estimateRevenue estimate
Valuation estimate
TechnoPhage leadership team
Management profileNumber of profiles
Profiles6 records
TechnoPhage subsidiaries and ownership
Company hierarchySubsidiaries2 records
TechnoPhage funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TechnoPhage M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TechnoPhage
What does TechnoPhage do?
TechnoPhage is a clinical-stage biopharmaceutical company developing bacteriophage-based therapeutics, antibody fragments, and repurposed small molecules for infections, neurological disorders, and ophthalmology. Its lead asset TP-102 is a five-phage cocktail for diabetic foot ulcers with FDA Fast Track designation, supported by an in-house INFARMED-certified GMP plant that also offers contract manufacturing for biologics.
Is TechnoPhage a public or private company?
TechnoPhage is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TechnoPhage founded?
TechnoPhage was founded in 2005. It employs 11 to 50 people.
Where is TechnoPhage based?
TechnoPhage is headquartered in Lisbon, Portugal, in the Europe region.
How does TechnoPhage make money?
Three revenue lines are on record. Biopharmaceutical Development and Commercialization is the primary driver. The others are contract Manufacturing Services (GMP) and collaborative R&D and Licensing.
Who are TechnoPhage's main competitors?
Direct peers on record are Intralytix, PHAXIAM Therapeutics, Armata Pharmaceuticals, Adaptive Phage Therapeutics and Locus Biosciences. Hovione is listed as an others. Emerging players are Eligo Bioscience and ContraFect Corporation. Regional players are Bial — Portela & Cª, S.A. and Medinfar Group.
Does TechnoPhage have an API?
No public API is recorded for TechnoPhage.